Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 251

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long‐term results of phase 3 randomized controlled trial

Li, Wen‐Fei, Chen, Nian‐Yong, Zhang, Ning, Hu, Guo‐Qing, Xie, Fang‐Yun, Sun, Yan, Chen, Xiao‐Zhong, Li, Jin‐Gao, Zhu, Xiao‐Dong, Hu, Chao‐Su, Xu, Xiang‐Ying, Chen, Yuan‐Yuan, Hu, Wei‐Han, Guo, Ling, Mo, Hao‐Yuan, Chen, Lei, Mao, Yan‐Ping, Sun, Rui, Ai, Ping, Liang, Shao‐Bo, Long, Guo‐Xian, Zheng, Bao‐Min, Feng, Xing‐Lai, Gong, Xiao‐Chang, Li, Ling, Shen, Chun‐Ying, Xu, Jian‐Yu, Guo, Ying, Chen, Yu‐Ming, Zhang, Fan, Lin, Li, Tang, Ling‐Long, Liu, Meng‐Zhong, Ma, Jun, Sun, Ying · 2019 · International Journal of Cancer

Abstract

To report long‐term results of a randomized controlled trial that compared cisplatin/fluorouracil/docetaxel (TPF) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) with CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC). Patients with stage III–IVB (except T3–4 N0) NPC were randomly assigned to receive IC plus CCRT (n = 241) or CCRT alone (n = 239). IC included three cycles of docetaxel (60 mg/m 2 d1), cisplatin (60 mg/m 2 d1), and fluorouracil (600 mg/m 2/d civ d1–5) every 3 weeks. Patients from both groups received intensity‐modulated radiotherapy concurrently with three cycles of 100 mg/m 2 cisplatin every 3 weeks. After a median follow‐up of 71.5 months, the IC plus CCRT group showed significantly better 5‐year failure‐free survival (FFS, 77.4%vs. 66.4%,p= 0.019), overall survival (OS, 85.6%vs. 77.7%,p= 0.042), distant failure‐free survival (88%vs. 79.8%,p= 0.030), and locoregional failure‐free survival (90.7%vs. 83.8%,p= 0.044) compared to the CCRT alone group.Post hoc subgroup analyses revealed that beneficial effects on FFS were primarily observed in patients with N1, stage IVA, pretreatment lactate dehydrogenase ≥170 U/l, or pretreatment plasma Epstein–Barr virus DNA ≥6000 copies/mL. Two nomograms were further developed to predict the potential FFS and OS benefit of TPF IC. The incidence of grade 3 or 4 late toxicities was 8.8% (21/239) in the IC plus CCRT group and 9.2% (22/238) in the CCRT alone group. Long‐term follow‐up confirmed that TPF IC plus CCRT significantly improved survival in locoregionally advanced NPC with no marked increase in late toxicities and could be an option of treatment for these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.32099

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

Metadata

Authors
Li, W., Chen, N., Zhang, N., Hu, G., Xie, F., Sun, Y., Chen, X., Li, J., Zhu, X., Hu, C., Xu, X., Chen, Y., Hu, W., Guo, L., Mo, H., Chen, L., Mao, Y., Sun, R., Ai, P., Liang, S., Long, G., Zheng, B., Feng, X., Gong, X., Li, L., Shen, C., Xu, J., Guo, Y., Chen, Y., Zhang, F., Lin, L., Tang, L., Liu, M., Ma, J., & Sun, Y.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2019-01-24
Volume
145
Issue
1
Pages
295-305
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2909326374
Cited by
251
References
1
FWCI
23.67
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.